All AbMole products are for research use only, cannot be used for human consumption.
TY 52156 is an orally bioavailable s1P3 receptor antagonist (Ki = 110 nM); inhibits S1P-induced Ca2+ release in HUVEC cells. TY 52156 suppresses FTY-720-induced S1P3 receptor-mediated bradycardia in vivo. TY 52156 also inhibits S1P-induced breast cancer stem cell expansion in vitro.
| Molecular Weight | 364.27 |
| Formula | C18H19Cl2N3O |
| CAS Number | 934369-14-9 |
| Solubility (25°C) | DMSO 36.43 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related S1P Receptor Products |
|---|
| VTX-002
VTX-002 is an orally active, selective S1P receptor 1 modulator for studies related to ulcerative colitis. |
| TRV045
TRV045 is an S1P receptor modulator that can be used in studies related to central nervous system disorders. |
| S1PR1 modulator 1
S1PR1 modulator 1 is a selective S1PR1 inhibitor, with a pIC50 of 7.6, with >40- and >80-fold selectivity, over the other S1PR isoforms S1PR2/3/4. |
| Ozanimod hydrochloride
Ozanimod (RPC-1063) hydrochloride, a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod hydrochloride has modulate effect for hS1P1 and hS1P5 receptor with EC50s of 1.03 nM and 8.6 nM, respectively. Ozanimod hydrochloride can be used for the research of relapsing multiple sclerosis (MS) . |
| Icanbelimod
Icanbelimod (S1p receptor agonist 1) is a potent and orally active S1P1 receptor agonist, exhibits an activity of inducing S1P1 internalization (EC50=9.83 nM). Icanbelimod has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
